Novo Nordisk Acquires 2seventy’s Gene Editing Technology and Haemophilia Candidate for $40 Million

1. Acquisition Details: Novo Nordisk has acquired 2seventy's gene editing technology, including the MegaTAL in vivo gene editing technology, and a haemophilia A program for $40 million.
2. Gene Editing Technology: The acquired technology is designed to enhance gene editing capabilities, particularly for haemophilia treatment.
3. Haemophilia Candidate: The haemophilia A program is a clinical-stage candidate that Novo Nordisk will further develop and potentially commercialize.
4. Novo Nordisk's Investment: This acquisition is part of Novo Nordisk's broader strategy to expand its gene therapy capabilities and invest in innovative technologies.